

# Supplement 2. Disclosure of Interest Forms of the ASH ISTH NHF WFH Guideline Panel on the Management of Von Willebrand Disease

Rezan Abdul-Kadir

Alice Arapshian

Nathan T. Connell

Susie Couper

Veronica Flood

Jean M. Grow

Peter Kouides

Michael Laffan

Michelle Lavin

Frank W. G. Leebeek

Reem Mustafa

Sarah H. O' Brien

Margareth C. Ozelo

Alberto Tosetto

Angela C. Weyand



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Biotest	Remuneration for lecture and travel expenses at XII international WFH forum	22/10/2017	<b>Not a COI.</b> Biotest operates plasma centers and markets plasma products. Factor VIII and prothrombin complex produced by Biotest may be used for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Abdul-Kadir has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Vifor	Honoraria for participating in Iron core steering committee	11/9/2017 But I will be attending next year meeting in July 2018	<b>Not a COI.</b> Vifor markets products for iron deficiency, chronic kidney disease, and infectious diseases, but not for bleeding disorders. This company will not be affected by guidelines on VWD.

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Iron core Supported by Vifor	I am a member of iron core expert team producing consensus documents on diagnosis and management of iron deficiency in clinical practice	Unpaid	Ongoing	<b>Not a COI.</b> As noted above, this company will not be affected by guidelines on VWD.

### Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

UK National guideline for management of pregnancy in women with inherited bleeding disorders

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No



Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

It would be supported considering the credibility of the process and the panel

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Obstetrics and Gynecology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Vifor Pharma	Attended Iron Academy meeting, July 2018	1/16/2020	<b>Not a COI.</b> Vifor Pharma is a pharmaceutical company that markets products to treat iron deficiency and over the counter medications. They do not market products to treat or diagnose VWD.
Vifor Pharma	Lecture on IDA in women at Levant Iron Academy, November 2019	1/16/2020	<b>Not a COI.</b> See above.
Pfizer	10 <sup>th</sup> Haemophilia Global Summit - Cochair and attended workshop on women and bleeding disorders. October 2019	1/16/2020	<b>Direct COI.</b> Pfizer markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD.
Shire/Takeda	Moderated symposium for ISTH virtual congress. All fees went to her institution.	6/30/2020	<b>Indirect COI.</b> Shire/Takeda market recombinant von Willebrand factor for the treatment of VWD.
Novo Nordisk	Talk at ISTH virtual congress. All fees went to her institution.	6/30/2020	<b>Indirect COI.</b> Novo Nordisk makes factor VIII that may be used in combination with factor VWF to treat VWD.

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 11/29/17; Castano, 3/15/18; Kunkle, 4/2/18 Holter-Chakrabarty, 5/7/2018	No	No	Dr. Abdul-Kadir has no current direct or indirect financial COIs.  Dr. Abdul-Kadir reports one recent paid activity with a company that may be affected by the guidelines (Biotest), but she has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.
Castano, 1/17/2020	Yes	Yes	Dr. Abdul-Kadir disclosed a new direct financial conflict with Pfizer. As noted above Pfizer makes products that may be affected by the guidelines. This conflict was managed through recusal.
7/22/2020	Yes	Yes	On July 2, 2020 Dr. Abdul-Kadir confirmed all information in this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Pfizer	Lecture at meeting.	1/16/2020	See parts D and E.

### Other Notes

Dr. Abdul-Kadir is an obstetrician. In her clinical practice she provides obstetric care to patients with bleeding disorders such as hemophilia. She was an author on a guideline for management of pregnancy in women with inherited bleeding disorders developed for the U.K. Royal College of Obstetricians and Gynaecologists, <a href="https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg71/">https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg71/</a> .
--



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- No
- Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

- No
- Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

- No
- Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- No
- Yes, as described below:

- Column 1 Name the company.
- Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>



# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

- No
- Yes, as described below:

- Column 1 Name the company funding or supporting the research.
- Column 2 Briefly describe the research project.
- Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
- Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

N/A

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

# Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 3/19/2018; Kunkle, 4/2/2018; Cheung 5/07/2018	No	No	Ms. Arapshian has no direct or indirect financial COIs with companies that could be affected by guidelines on management of VWD.
7/22/2020	No	No	On July 7,2020 Ms. Arapshian confirmed all information in this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

### Other Notes

Ms. Arapshian is serving as a patient representative on the guideline panel.
--





# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novimmune	An observational, multicenter study to evaluate interferon gamma (IFNγ) and other inflammatory mediators in Adult Patients with hemophagocytic lymphohistiocytosis (A-HLH)	Site subinvestigator to enroll patients	Current	<b>Not a COI.</b> Novimmune does not market any products for the diagnosis or treatment of VWD.
Genentech; Hoffmann-La Roche	A randomized, multicenter, open-label, phase iii clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in	Site subinvestigator to enroll patients	Current	<b>Not a COI.</b> Dr. Connell does not have a leadership role in this study. Genentech and Hoffmann-LaRoche do not market any products for the diagnosis or

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	hemophilia A patients without inhibitors			treatment of VWD. Dr. Connell does not have a leadership role in this study.
Daiichi	A Phase 3B, Prospective, Randomized, Open-Label, Blind Evaluator (Probe) Study Evaluating the Efficacy and Safety of (LMW) Heparin / Edoxaban Versus Dalteparin in Venous Thromboembolism Associated with Cancer	Site subinvestigator to enroll patients	Current	<b>Not a COI.</b> Daiichi does not market any products for the diagnosis or treatment of VWD.
Bristol-Myers Squibb	Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS0986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)	Site subinvestigator to enroll patients	12/8/16 (no patients enrolled at site prior to closure)	<b>Not a COI.</b> BMS does not market any products for the diagnosis or treatment of VWD.
Pharmacosmos AS	A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia who are intolerant or unresponsive to oral iron therapy or in whom the haemoglobin measurement in Investigators' opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.	Site subinvestigator to enroll patients	Current	<b>Not a COI.</b> Pharmacosmos AS does not market any products for the diagnosis or treatment of VWD.

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease  
ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:



I am a local clinician in the field of benign hematology which includes topics of thrombosis and hemostasis. I see patients clinically in these fields and teach about the diagnosis and management of hematologic disorders to medical students, medical residents, hematology/oncology fellows based on currently published evidence-based guidelines.

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I have strong institutional support from the Brigham and Women's Hospital Division of Hematology to participate in these guidelines and believe they would support evidence-based recommendations that would result from the process.

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
ISTH	ISTH has published various papers to try and standardize the terminology and diagnosis of VWD. They are participating in these guidelines.	Member

## Clinical Practice

9. Do you see patients clinically?

- No  
 Yes

If yes, what is your primary specialty or subspecialty?

Hematology with a focus on thrombosis and hemostasis

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No  
 Yes

If yes, please explain:

I prescribe various treatments for von Willebrand disease such as plasma-derived factor, recombinant factor, antifibrinolytics, and DDAVP as appropriate and supported by published evidence.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No  
 Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Global Blood Therapeutics, Inc.	Site sub-investigator to enroll patients for a Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease (ongoing)	10/29/2017	<b>Not a COI.</b> Global Blood Therapeutics does not market any products for the diagnosis or treatment of VWD.
Genentech; Hoffmann-La Roche	Update, this activity ended on March 31, 2017 See part B.	1/09/2020	<b>Not a COI.</b>
Daiichi	Update, this activity ended on 5/2/2018 See part B.	1/09/2020	<b>Not a COI.</b>
Bristol-Myers Squibb	Update, this activity ended on 12/8/2016 See part B.	1/09/2020	<b>Not a COI.</b>
Pharmacosmos AS	This activity ended and the institution closed on 1/25/2018. See part B.	1/09/2020	<b>Not a COI.</b>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 7/27/17; Kunkle, 4/2/18; Djulgovic, 5/07/2018	No	No	Dr. Connell has no current direct or indirect financial conflicts of interest with companies that market products that could be affected by guidelines on the diagnosis or treatment of von Willebrand disease.
Castano, 1/9/2020	No	No	Dr. Connell updated his disclosures to report end dates to several research activities he has been involved in. Dr. Connell has no current direct or indirect financial conflict of interest.
Castano, 7/14/2020	No	No	On 7/01/2020 Dr. Connell confirmed all information on this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

### Other Notes

Dr. Connell is a hematologist specializing in thrombosis and hemostasis. In his clinical practice, he treats patients with von Willebrand disease. For his institution, he teaches medical students, residents, and fellows about the diagnosis and management of hematologic disorders. As a site sub investigator, he enrolls patients into research studies that are funded by pharmaceutical companies; however, none of the companies markets products used for the diagnosis or treatment of von Willebrand disease.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has your partner or spouse had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,



markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: The introduction and adoption of clear and comprehensive Guidelines is crucial to the improved treatment of people with Von Willebrand Disease internationally.

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Not relevant – my career does not relate to my work on this panel as I am employed in the banking industry.

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

- No  
 Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No  
 Yes

If yes, please explain:

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No  
 Yes

If yes, please describe:

# Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 03/16/2018; Kunkle 4/2/2018; Holter-Chakrabarty, 5/7/2018	No	No	Ms. Couper has no direct or indirect financial COIs with companies that could be affected by guidelines on management of VWD.
Castano, 7/22/2020	No	No	On July 5,2020 Ms. Couper confirmed all information on this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

### Other Notes

Ms. Couper is serving as a patient representative on the guideline panel.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:



Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire	Consultant	March 2017	<b>Not a COI.</b> Shire markets recombinant von Willebrand factor for the treatment of VWD and anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Flood has agreed to avoid direct financial conflicts for the duration of the guideline development process.
CSL Behring	Consultant	May 2017	<b>Not a COI.</b> CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Flood has agreed to avoid direct financial conflicts for the duration of the guideline development process.

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: just that these guidelines are important to clinicians and patients with VWD

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

A published paper suggesting that von Willebrand disease patients benefit from comprehensive care , published this month in Haemophilia (23(4):e370-374, July 2017)

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
NIH	Biology of VWF-collagen interactions	Principal investigator	December 2020

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don’t know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don’t know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don’t know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I believe that this work might aide in my ability to be promoted, but I have sufficient national recognition to be promoted without this committee. My institution is supportive of my work in this area, and will help me maintain sufficient time to participate.

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>



<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

- No
- Yes

If yes, what is your primary specialty or subspecialty?

Pediatric hematology including patients with VWD

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No
- Yes

If yes, please explain:

I diagnose and treat patients with von Willebrand disease and prescribe medications for their conditions.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No
- Yes

If yes, please describe:

I intend to refrain from any interactions with pharmaceutical companies for the foreseeable future while working on these guidelines

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	Member, Scientific Committee on Hemostasis, ASH	9/21/2017	<b>Not a COI</b>
N/A	Publication: manuscript reviewing VWD diagnosis in the United States for a special VWD issue of Annals of Hematology (submitted, pending review)	11/13/2017	<b>Not a COI</b>
N/A	Publication: manuscript reviewing VWD diagnosis and briefly treatment, accepted to Research and Practice in Thrombosis and Haemostasis	11/13/2017	<b>Not a COI</b>
N/A	A talk and associated manuscript at ASH 2017 on new updates in diagnosis and treatment of VWD, manuscript to be published in Blood	11/13/2017	<b>Not a COI</b>
N/A	Member of NHLBI MPOR Standing Panel - NHLBI Mentored Patient Oriented Research review group July 2018 – June 2020	4/18/2018	<b>Not a COI</b>
N/A	Abstract submissions to ASH Annual Meeting 2018. One about the basic science of VWF and myosin and one on the diagnosis of VWD. She is also preparing a paper on a mouse model of VWD.	7/10/2018	<b>Not a COI</b>
N/A	CME activity sponsored by CDC on improving Outcomes for VWD. <a href="https://www.impactedu.net/bleeding/">https://www.impactedu.net/bleeding/</a>	8/10/2019	This was an ACCME-accredited activity, and Dr. Flood did not receive any direct payments from industry.

# Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

## Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 7/27/17; Castano, 03/16/18; Kunkle, 4/2/18; Holter-Chakrabarty, 5/7/2018	No	No	Dr. Flood does not have any current direct or indirect financial COIs. In 2017, prior to her appointment to the guideline panel, she did paid consulting for two companies that market products used for the treatment of VWD (Shire and CSL Behring). She has agreed to avoid direct financial COIs with affected companies for the duration of the guideline development process.
Castano, 11/21/2019	No	No	In August 2019 Dr. Flood reported a CME activity sponsored by CDC.
Castano, 7,22,2020	No	No	On July 1, 2020 Dr. Flood confirmed all information on this form.

## Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

## Other Notes

Dr. Flood is a pediatric hematologist. In her clinical practice she diagnoses and treats patients with VWD. She has given talks and authored articles about the diagnosis and treatment of VWD. She is the principal investigator for an NIH-sponsored study about the biology of VWF-collagen interactions.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:



# Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

## Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

## Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Conducted Focus Groups exploring patients responses to Hep C P.S.A.s Grow + Christopher (2008)  
“Breaking the Silence Surrounding Hepatitis C by Promoting Self-Efficacy: Hepatitis C Public Service Announcements” in Qualitative Health Research, 18/10, pp. 1401-12.

**ASH Internal Note:** Management of VWD was not directly addressed by this research project or article: <http://journals.sagepub.com/doi/pdf/10.1177/1049732308322603>.

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would be strongly approved.

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Castano, 3/19/2018; Kunkle, 4/2/2018; Cheung, 5/07/2018	No	No	Dr. Grow has no direct or indirect financial COIs with companies that could be affected by guidelines on management of VWD.
Castano, 7/22/2020	No	No	On July 1, 2020 Dr. Grow confirmed all information on this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

### Other Notes

Dr. Grow is serving as a patient representative on the guideline panel.
---



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.



Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

Please note none of the below were on-going relationships- only one time meetings and moving forward no future consulting or speaking planned

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Octapharma	Speaker at a symposium	7/2016	<b>Not a COI.</b> Octapharma markets a VWF replacement therapy for the treatment of patients with VWD. They also market a recombinant factor VIII product for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Kouides has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Shire (Baxter)	Speaker at a symposium	7/2016	<b>Not a COI.</b> Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Kouides has agreed to avoid direct financial conflicts for the duration of the guideline development process.
CSL Behring	Advisory Board – 1 meeting	10/2016	<b>Not a COI.</b> CSL Behring markets human plasma-derived von Willebrand factor and FVIII (HP-VWF/FVIII) concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Kouides has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Bioverativ	Advisory Board – 1 meeting	4/2017	<b>Not a COI.</b> Bioverativ markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Kouides has agreed to avoid direct financial conflicts for the duration of the guideline development process.

### My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bioverativ	Eloctate Pase 3 Study	Local PI	6/2018	<b>Indirect COI.</b> Bioverativ markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWD in the treatment of VWD. Although Dr. Kouides does not have a leadership role in this research, these products may be affected by the guidelines.

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

I am serving with Drs. Jill Johnsen and Barbara Konkle of the University of Washington as co-principal investigators of a North American multicenter investigator initiated study entitled **Von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in von Willebrand Disease for Childbirth**. This study will be sponsored by Octapharma which manufactures Wilate. We have proposed this study and are in the process of finalizing the protocol. **Indirect COI, Octapharma markets products that may be affected by the guidelines.**

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Invited editorial for the journal Haemophilia 2015 16. (Kouides PA. Preventing postpartum haemorrhage-when guidelines fall short. Haemophilia. 2015 Apr 30) that reviewed present guidelines on managing PPH.

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

There would be no ramifications.

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology, primarily thrombosis and hemostasis.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I evaluate and manage patients with von Willebrand disease and carry out several clinical studies of VWD.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:



## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
UniQure	Head of the drug monitoring training safety board (DMTSB), I review the study protocol and data in terms of safety regarding adverse events for a gene therapy product for hemophilia B involving only factor IX.	7/23/2018	<b>Not a COI.</b> UniQure does not market any products for the diagnosis or treatment of VWD, and therefore will not be affected by the guidelines.
Octapharma	Co-PI - research about von Willebrand factor, VWF replacement therapy for childbirth	7/23/2018	<b>Indirect COI.</b> See above.
Bayer Pharmaceuticals	Lunch at Hemophilia Center 12/23/2019	9/23/2019	<b>Not a COI.</b> Bayer is a pharmaceutical company that markets hormonal products that can be used to treat women with VWD. However, they are marketed to a large population and VWD is a rare disease. Any effects on the company are expected to be negligible and do not present a conflict of interest.
Genentech USA Inc.	Food and Beverage	9/23/2019	<b>Indirect COI.</b> Genentech is a part of Roche, a pharmaceutical and diagnostic company that markets an assay (RISTOtest) for the in

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			vitro determination of von Willebrand Factor outside the US that can be affected by the Diagnosis guidelines.
Jazz Pharmaceuticals	Lunch at Hemophilia Center 10/03/2018	9/23/2019	<b>Not a COI.</b> Jazz pharmaceuticals does not make any products for the treatment or diagnosis of VWD.
Novo Nordisk	Lunch at Hemophilia Center 2/22/ and 3/01, 2018	9/23/2019	<b>Indirect COI.</b> Novo Nordisk markets recombinant factor VIII. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.
Rigel Pharmaceuticals	Lunch at Hemophilia Center 12/05/2018	9/23/2019	<b>Not a COI.</b> Rigel Pharmaceuticals does not market products for the diagnosis or treatment of VWD.
Z-Medica, LLC	Lunch at Hemophilia Center 8/03/2018	9/23/2018	<b>Not a COI.</b> Z-Medica does not market products for the diagnosis or treatment of VWD.
Octapharma	Food and beverage 5/09/2019 reported in Open Payments.  Dr. Kouides explained that this was a sponsored reception at the HTRS annual meeting. He did not take any meals and the transfer of value was in the form of a meal.	7/07/2020	<b>Not a COI.</b> See above, see Description.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
CSL Behring	<p>Educational activity 10/08/2019</p> <p>This activity was discovered via Open Payments, however Dr. Kouides indicated this is an error and explained that he did not purposely attend any sponsored events by CSL Behring. He thinks this may have been a sponsored event at the NHF annual meeting. He did not take any fees and the transfer of value may have been in the form of a meal.</p>	7/07/2020	<p><b>Not a COI.</b> CSL Behring makes desmopressin which is used for the treatment and diagnosis of VWD. <b>Please see Description.</b></p>
E.R, Squibb & Sons	<p>Food and Beverage 5/13/2019. Reported in open payments.</p>	7/07/2020	<p><b>Not a COI.</b></p>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/2017; Castano, Kunkle 3/13/18, Cheung 5/07/2018	No	Yes	<p>Dr. Kouides has potential indirect conflicts with companies that may be affected by the guidelines depending on scope, including Bioverativ (non-leadership role about recombinant factor VIII) and Octapharma (expected co-leadership role on research about von Willebrand factor (VWF) replacement therapy for childbirth).</p> <p>Dr. Kouides reports recent paid activities with companies that may be affected by the guidelines (Octapharma, Shire, CSL Behring, Bioverativ), but he has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.</p>
Castano, 7/27/2018	No	Yes	Dr. Kouides is participating in a review of a gene therapy for hemophilia B, developed by UniQure. UniQure does not market products that could be affected by the guidelines.
Castano, 11/20/2019	No	Yes	Dr. Kouides disclosed two indirect conflicts with Genentech, which is a part of Roche, and with Novo Nordisk.
Castano, 07/30/2020	No	Yes	On July 29, 2020 Dr. Kouides confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Kouides is a hematologist. He treats patients with thrombosis and hemostasis, but also evaluates and manages patients with VWD. Dr. Kouides authored an editorial on preventing postpartum hemorrhage that reviewed present guidelines.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Roche	Advisory board	July 2017	<b>Not a COI.</b> Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand factor. Outside the US. Roche markets a prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII. This activity concluded prior to initiation of the guidelines.
Pfizer	Speaker fees	Ongoing	<b>Direct COI.</b> Pfizer markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD.
Pfizer	Grant review panel	April 2018	<b>Not a COI.</b> As noted above, Pfizer markets products that could be addressed by the guidelines. This activity may represent a COI depending on the scope of the guidelines.
LFB	Travel support	Dec 2016	<b>Not a COI.</b> LFB markets a human plasma-derived VWF concentrate for the treatment of VWD. At the time of review, this therapy is only available in Europe. This activity concluded prior to initiation of the guidelines, and Dr. Laffan has agreed to avoid direct financial conflicts with this company for the duration of the guideline development process.
Sobi	Travel support	Dec 2016	<b>Not a COI.</b> Sobi markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines.
Sobi	Consultancy fees	Dec 2016	<b>Not a COI.</b> As noted above, Sobi markets products that could be addressed by the guidelines. This activity concluded prior to initiation of the guidelines.
Bayer	Speaker fees	April 2018	<b>Not a COI.</b> Bayer markets hormonal products that can be used in the treatment of women with VWD.



## My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Part B. Indirect Financial Interests in or Relationships With Companies

### Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Biomarin	Gene therapy for haemophilia	PI	ongoing	<b>Not a COI.</b> BioMarin markets products for rare genetic diseases that do not include bleeding disorders. They have one pipeline product in Phase 2 for treatment of hemophilia A. The therapy under investigation, in this research is not related to VWD.
CSL Behring	Post marketing study of Voncento use	PI	Nov 2017	<b>Not a COI.</b> CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines.

### Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

# Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

## Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

## Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

As chair of the UKHCDO working party on von Willebrand disease I am the author of previously published guidelines on von Willebrand disease (**The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology British Journal of Haematology (2014) 167: 453–465**)

## Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
UK Haemophilia Doctors Organisation	Analysis of national registration data	Chair of working party	Ongoing

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Imperial College encourages participation in panels such as this. However, I do not think it would materially affect my position within Imperial College.

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
UKHCDO	Published guidelines as noted in point 2. Above.	Author

## Clinical Practice

9. Do you see patients clinically?

- No  
 Yes

If yes, what is your primary specialty or subspecialty?

Haematology – Haemostasis and thrombosis

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

- No  
 Yes

If yes, please explain: I am responsible for the management of patients with von Willebrand disease as well as other bleeding disorders. I make decisions regarding choice of treatment, although these decisions are within nationally agreed guidelines.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

- No  
 Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Shire/Takeda	Travel assistance for presentation no additional payment received.	4/3/2018	<b>Not a COI.</b> Upon disclosure, Dr. Laffan agreed to avoid direct financial conflicts with this company for the duration of the guideline development process.
CSL Behring	Travel assistance	4/3/2018	<b>Not a COI.</b> See above.
Pfizer	Dr. Laffan clarified that the Pfizer speaker activity is ongoing (see Part A page 3). As noted above Pfizer makes products that can be affected by the guidelines.	6/28/2018	<b>Direct COI.</b> See part A, page 3
Leo Pharma	Lecturing.	9/28/2018	<b>Not a COI.</b> Leo Pharma does not market any products for the diagnosis or treatment of bleeding disorders.
Roche	Consulting on management of hemophilia.	9/28/2018	<b>Indirect COI.</b> Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US that may be affected by the Diagnosis Guidelines.
Biomarin	Advisory Board	12/02/2019	<b>Not a COI.</b> As noted above, Biomarin does not market any products for the treatment or diagnosis of VWD.



<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
SOBI	Advisory Board	12/02/2019	<b>Indirect COI.</b> As noted above SOBI markets a recombinant factor VIII product that may be used in conjunction with recombinant VWF in the treatment of VWD.
Portola	Advisory Board	12/15/2019	<b>Not a COI.</b> Portola does not market any products for the treatment or diagnosis of VWD.
Bayer	Speaker fees	12/15/2019	<b>Not a COI.</b> Bayer markets some hormonal therapies (contraceptive therapies) that can be use for the treatment in VWD in women. However, these therapies are marketed to a wide population and the effect of the guidelines is expected to be negligible.
Novo Nordisk	Speaker fees	01/02/2019	<b>Indirect COI.</b> Novo Nordisk markets a recombinant factor VIII product that may be used in conjunction with recombinant VWF in the treatment of VWD.
Roche	Speaker fee – Sept. 2019	01/08/2019	<b>Indirect COI.</b> See above.
Shire/Takeda	Talk at conference, but Dr. Laffan declined the fee.	07/08/2020	<b>Indirect COI</b> See above.

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/2017;  Castano, 03/15/2018;  Cheung, 5/07/2018	No	No	Dr. Laffan has no direct or indirect financial COIs.  Dr. Laffan reports three past paid activities with Roche, LBF, and Sobi; companies that can be affected by the guidelines. He has agreed to avoid direct financial conflicts with these companies for the duration of the guideline development process.
Castano, 04/03/2018	No	See above	On April 3, 2018, Dr. Laffan reported receiving travel assistance from Shire and CSL Behring. Upon disclosure, he agreed to avoid direct financial conflicts with this and all affected companies for the duration of the guidelines development process.
Castano, 7/23/2018	Yes	Yes	Dr. Laffan has a direct financial conflict with Pfizer. On 6/28 Dr. Laffan clarified that the Pfizer speaker activity is ongoing (see Part A page 3). As noted above Pfizer makes products that can be affected by the guidelines.
Castano, 9/28/2018	Yes	Yes	New Disclosure: Dr. Laffan accepted a consultancy on hemophilia with Roche, which constitutes an indirect financial conflict. Roche makes a test that can be affected by the Diagnosis guidelines.
Castano, 12/02/2019	Yes	Yes	New Disclosure: On December 2, 2019 Dr. Laffan disclosed two advisory board activities with Biomarin and SOBI. Biomarin does not make any products for the treatment or diagnosis of VWD so this is not a COI. The SOBI activity is an indirect COI because they market a factor VIII products that may be used along with factor VWF products

			to treat VWD and could be indirectly affected by the guidelines.
Castano, 1/11/2020	Yes	Yes	<p>New Disclosures: On December 15, 2019 Dr. Laffan disclosed two activities with Portola and Bayer that do not constitute conflicts of interest. Portola does not make any products that will be affected by the guidelines, and although Bayer makes hormonal therapies for VWD, these are marketed to a wide population and the effects of the guidelines are expected to be minimal.</p> <p>On January 2, 2020 Dr. Laffan disclosed a new speaking activity with Novo Nordisk. This is an indirect COI because Novo Nordisk markets a factor VIII product that may be used along with factor VWF products to treat VWD and can be indirectly affected by the guidelines. On January 8, Dr. Laffan disclosed an activity with Roche which is an indirect conflict, see above for details.</p>
Castano, 07/22/2020	Yes	Yes	Dr. Laffan disclosed an indirect conflict, a talk at a conference for Takeda/Shire for which he declined the speaker fee. On July 8, 2020 Dr. Laffan confirmed all information on this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Pfizer	Ongoing speaking activity	6/28/2018	<b>Direct COI</b> see above.

### Other Notes

Dr. Laffan is a hematologist. He focuses on hemostasis and thrombosis, as well as the management of patients with bleeding disorders including VWD.

Dr. Laffan is the chair of a UKHCDO (The United Kingdom Haemophilia Centre Doctors' Organization) working party on VWD, where he oversees analysis of UK national register data. He is also the author of previously published guidelines on von Willebrand disease sponsored by UKHCDO.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire/Baxalta/ Takeda	Advisory Board on extended half life hemophilia products	June 2, 2016	<b>Not a COI.</b> Shire markets recombinant von Willebrand factor for the treatment of VWD and anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Lavin has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Shire/Takeda	Advate physician workshop	January 2018	<b>Not a COI.</b> As noted above, Shire markets products that could be addressed by the guidelines. This activity concluded prior to initiation of the guidelines, and Dr. Lavin has agreed to avoid direct financial conflicts for the duration of the guideline development process.

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Michelle Lavin MB, BCh, BAO (Hons), MRCPI, FRCPath (Royal College of Surgeons in Ireland)

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire/Takeda	Co-funded a research project with Science Foundation Ireland	Clinical research fellow	August 2021	<b>Indirect COI.</b> As noted above, Shire markets products that could be addressed by the guidelines.

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?



No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Generic review article for ASH Education Program on new treatment approaches to VWD

ASH Education Program 2016, Dec 2; 2016(1), 683-89

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I have a supportive mentor who is happy for me to be involved in this process.

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology - coagulation

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I am involved in the routine workup of patients with possible bleeding disorders and as such order investigations for workup of same.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Shire/Takeda	Talk for World Hemophilia Day for local hemophilia group, no fee taken on April 17, 2018, no fees were received for this talk.	6/13/2018	<b>Indirect COI.</b> As noted above Shire/Takeda markets products that can be affected by the guidelines.
Siemens	Talk at international hemostasis symposium, Feb. 2019	6/13/2018	<b>Not a COI.</b> Siemens does not market any products for the treatment of VWD.
Shire/Takeda	Talk to present research results in Vienna Austria in March 2019, travel was covered but no fees were paid.	9/24/2019	<b>Direct COI.</b> As noted above Shire/Takeda markets products that can be affected by the guidelines.
Shire/Takeda	Ended research project with Science Foundation Ireland on July 31, 2019.	9/24/2019	<b>Not a COI.</b> This indirect conflict noted in part B has ended.
N/A	Faculty for COR2ED, an independent medical educational company based in Europe. Dr. Lavin is will be teaching about VWD, as part of a grant funded by Takeda, but will not be receiving funds directly from industry, but rather through CORE2ED.	2/18/2020	<b>Indirect COI.</b> As noted above Shire/Takeda markets products that can be affected by the guidelines.
Tremeau Pharmaceuticals	Member, Advisory Board.	2/28/2020	<b>Not a COI.</b> Tremeau Pharmaceuticals does not currently market any products that can

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			be affected by these guidelines.
N/A	SH Education programme 2019, Perioperative management of VWD; 2019 Blood article, How I treat patients with Low VWF.	7/03/2020	<b>Not a COI.</b>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/2017; Castano, 03/16/2018; Kunkle, 4/2/2018; Holter-Chakrabarty, 5/07/2018	No	Yes	Dr. Lavin has no current direct financial COIs with companies that could be affected by guidelines on managing VWD. She has one potential indirect financial conflict with Shire, a company that can be affected by the guidelines. She reports two recent paid activities with Shire, a company that may be affected by the guidelines, but she has agreed to avoid direct financial COIs including with Shire during the guideline development process.
Castano, 7/20/2018	No	Yes	Dr. Lavin gave a talk sponsored by Shire/Takeda during World Hemophilia Day on April 17, 2018 but took no payment. Shire/Takeda is a company that markets products that can be affected by the guidelines.
Castano, 11/20/2019	Yes	Yes	On September 2019 Dr. Lavin disclosed that one of her research activities with Takeda/Shire ended in July 2019, see parts B and D. Dr. Lavin gave a talk sponsored by Shire/Takeda to present research results, she took no payment but travel to Vienna Austria was paid by Shire/Takeda, this is a direct financial conflict that was managed through recusal.
Castano, 7/02/2020	Yes	Yes	In February 2020, Dr. Lavin joined an educational program sponsored by Takeda, which constitutes an indirect COI, see part D.
Castano, 7/22/2020	Yes	Yes	On July 3, 2020 Dr. Lavin confirmed all information on this form.



### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Shire/Takeda	Travel for research talk on March 2019 in Vienna Austria	9/24/2019	<b>Direct COI.</b> As noted above Shire/Takeda markets products that can be affected by the guidelines.

### Other Notes

Dr. Lavin is a hematologist specializing in coagulation. In her clinical practice, she is involved in the routine workup of patients with possible bleeding disorders. She presented and authored a recent review of treatment approaches to VWD. Dr. Lavin co-authored an article about new treatment approaches to VWD titled "[von Willebrand Disease: Rediscovering an Old Disease](#)" in ASH's *Hematology, The Education Program*.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Roche	Data safety monitoring board	ongoing	<b>Indirect COI.</b> Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor outside the US. Roche also markets a prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors. If these products are addressed by the guidelines, this activity will be viewed a direct conflict.
Roche	Travel support for ASH meeting 2017	ongoing	<b>Not a COI.</b> Although Roche could be affected depending on the guideline scope, Dr. Leebeek has agreed to avoid direct financial conflicts during the guidelines development process.
NovoNordisk	Advisory board (fee to the university)	Dec 2016	<b>Not a COI.</b> Novo Nordisk markets recombinant factor VIIa and a recombinant factor VIII for treatment of Hemophilia A. These products are not recommended for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Leebeek has agreed to avoid direct financial conflicts for the duration of the guideline development process. In this case, payments were distributed to the institution rather than to the individual.
uniQure	Consultant for gene therapy study (fee to the university)	ongoing	<b>Not a COI.</b> UniQure is developing a pipeline of gene therapies for conditions such as hemophilia A and B and Huntington's disease. They do not currently have any products indicated for the diagnosis or treatment of VWD.
Baxalta / Shire	Advisory board (fee to the university)	July 2017	<b>Not a COI.</b> Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Leebeek has agreed to avoid

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			direct financial conflicts for the duration of the guideline development process. In this case, payments were distributed to the institution rather than to the individual.
Roche	Speakers fee at ASH review 2017 in the Netherlands	December 2017	<b>Not a COI.</b> This activity ended prior to appointment to the guidelines panel.

### My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
CSL Behring	Willebrand in the Netherlands study (WiN study)	PI	ongoing	<b>Indirect COI.</b> CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. These products may be addressed by the guidelines.
Shire	Whole exome sequencing in willebrand disease (WiN study)	PI	ongoing	<b>Indirect COI.</b> As noted above Shire markets products that can be used in the treatment of VWD. These products may be addressed by the guidelines.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:



## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I have been the editor of the Dutch guidelines on haemophilia and related bleedings disorders in 2009.

Review articles:

1. Leebeek FWG. Diagnostiek en behandeling van de aangeboren en verworven vorm van de ziekte van von Willebrand. Ned Tijdschr voor Hematologie 2004;1:8-16
2. Leebeek FWG, de Wee EM. Von Willebrand type 3: an update. Hematology Education 2010;4:74-78.

3. Leebeek FWG, Mauser-Bunschoten EP. Nieuwe richtlijn diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. Ned Tijdschr Hematologie 2010;7:107-114.
4. de Wee EM, Leebeek FWG, Eikenboom JCJ. Diagnosis and management of von Willebrand disease in the Netherlands. Semin Thromb Haemostas 2011;37:480-7.
5. Sanders YV, de Wee EM, Meijer K, Eikenboom J, van der Bom JG, Fijnvandraat CJ, Laros-van Gorkom BA, Cnossen MH, Mauser-Bunschoten EP, Leebeek FWG. Von Willebrand disease in the Netherlands: the WiN study. Nederland Tijdschrift Geneeskunde. 2014;158:A6518. Dutch.
6. Boender J, Kruij MJ, Leebeek FW. A diagnostic approach to mild bleeding disorders. J Thromb Haemost. 2016 Aug;14(8): 1507-16.
7. F.W.G. Leebeek, J.C.J. Eikenboom Von Willebrand's Disease. N Engl J Med 2016; 375:2067-2080
8. Leebeek FWG, Susen S. Von Willebrand disease: Clinical conundrums. Haemophilia 2018; accepted for publication

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
Dutch haemophilia Foundation	Willebrand in the Netherlands Study	PI	ongoing

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

It is highly appreciated by our institution to be part of an international guideline committee

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I diagnose and treat patients with bleeding disorders, including patients with von Willebrand disease. I prescribe drugs and coagulationfactor concentrates, such as FVIII/VWF concentrates as treatment or prophylaxis for bleeding in these patients.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Stago Diagnostica (S.A.S. ) France	Author of a chapter in "Practice manual "in bleeding disorders. The Chapter is entitled Clinical aspects of von Willebrand disease	6/05/2018	<b>Indirect COI.</b> Stago is a pharmaceutical laboratory that markets diagnostic assays used in the for VWD. These tests can be affected by the guidelines depending on the final PICO questions.
Shire/Takeda	Talk on February 6, 2019 at The European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Prague entitled Personalized treatment scenarios in von Willebrand disease. The fee for this talk was paid to Erasmus University Medical Center and not directly to Dr. Leebeek.	1/18/2019	<b>Indirect COI.</b> As noted above Shire/Takeda makes products that can be affected by the guidelines. The fee for this talk was paid to Erasmus University Medical Center and not directly to Dr. Leebeek.
N/A	Dr. Leebeek disclosed that he is involved in a guideline effort addressing four bleeding disorders one of which is VWD. This effort is led by the European Hematology Association, EHA. Dr. Leebeek is a sub-coordinator.	1/18/2019	<b>Not a COI.</b> After careful consideration by with both clinical chairs from the diagnosis and management panels it was determined that there was not enough overlap between the methods and content of the EHA and the ASH, ISTH, NHF, VWH VWD Guidelines to consider this a conflict.
Shire/Takeda	Travel support to attend the European Association	1/16/2020	<b>Direct COI.</b> As noted above Shire/Takeda

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	for Haemophilia and Allied Disorders (EAHAD) meeting in Prague on February 6, 2019 (see above).		makes products that can be affected by the guidelines.
Shire/Takeda	Phase III study to investigate the use of prophylaxis of concentrate in VWD.	1/16/2020	<b>Indirect COI.</b> See above.
CSL Behring	VIP Study, study about blood coagulation and fibrosis.	1/16/2020	<b>Not a COI.</b> This study ended prior Dr. Leebeek's to appointment to the guidelines.
Shire/Takeda	Study on use of recombinant VWF to treat bleeding in patients with VWD	1/16/2020	<b>Not a COI.</b> This study ended prior Dr. Leebeek's to appointment to the guidelines.
SOBI	Travel Support ISTH meeting in Melbourne Australia, July 2018	7/6/2020	<b>Indirect COI.</b> SOBI manufactures factor VIII that can be used in combination with factor VWF to treat VWD.
SOBI	Research support for a study on dental care in patients with bleeding disorders, 2019.	7/6/2020	<b>Indirect COI.</b> See above.
N/A	Published article: Leebeek FWG, Atiq F. How I manage severe von Willebrand disease. Br. J Haematol 2019;187:418-430	7/6/2020	<b>Not a COI</b>
N/A	Published article: Leebeek FWG, Duvekot J, Kruip MJHA. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease.	7/6/2020	<b>Not a COI</b>

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	Blood 2020; accepted for publication		

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 1/29/18; Castano, Kunkle, 3/13/18 ; Holter-Chakrabarty, 5/7/2018	No	Yes	Dr. Leebeek has indirect conflicts with companies that may be affected by the guidelines depending on scope, Roche (DSMB); CSL Behring (leadership role on WiN study), Shire (leadership role on WiN study whole exome sequencing).  Dr. Leebeek has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Castano, 7/27/2018	No	Yes	New Disclosure: Dr. Leebeek authored a book chapter on bleeding disorders for Stago Diagnostica, a company that can indirectly be affected by the guidelines. See part D.
Castano, 1/18/2019	No	Yes	New Disclosure: Dr. Leebeek gave a talk during an EAHAD meeting in Prague, sponsored by Shire/Takeda, but the fee was paid to his institution, Erasmus University Medical Center. Dr. Leebeek also disclosed his participation on a set of guidelines on bleeding disorders that includes a guideline on VWD. Please see part D.
Castano, 1/16/2020	Yes	Yes	On January 16, 2020, Dr. Leebeek disclosed a direct financial conflict with Shire/Takeda, who make a product for the treatment of VWD and therefore will be affected by the guidelines. This was managed through disclosure. In addition, Dr. Leebeek disclosed a research activity with Shire/Takeda, which constitute an indirect conflict, see part D.
Castano, 7/22/2020	Yes	Yes	On July 6, 2020 Dr. Leebeek disclosed two activities with SOBI which constitute indirect



			financial conflicts. One activity was sponsored travel to and ISTH meeting and the other, a research activity for which he is the responsible physician. Dr. Leebeek also disclosed two recent published articles on VWD, see part D for details. On July 2020 Dr. Leebeek also confirmed all information on this form.
--	--	--	---

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Shire/Takeda	Travel support to attend the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Prague on February 6, 2019 (see above).	1/16/2020	

Other Notes

Dr. Leebeek is a hematologist. In his clinical practice, he diagnoses and treats patients with bleeding disorders, including patients with VWD. He was the editor of 2009 Dutch guidelines on hemophilia and related bleedings disorders and has published review articles about VWD.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease  
ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:



6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I suspect they will be supportive but I don't really know.

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Nephrologist

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Diagnosis of von Willebrand Disease ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Kunkle, 3/16/18; Lottenberg, 5/10/2018	No	No	Dr. Mustafa has no direct or indirect conflict of interests with companies that can be affected by the guidelines.
Castano, 7/31/2020	No	No	On July 31, 2020 Dr. Mustafa confirmed all information on this from.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

### Other Notes

Dr. Mustafa is a nephrologist and methodologist. In her clinical practice, she does not diagnose or treat patients with von Willebrand disease. Under an agreement between ASH and the University of Kansas Medical Center, she is leading systematic reviews of available evidence for these guidelines.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bristol Myers Squibb	Steering Committee Principal Investigator Travel Reimbursement Topic – VTE prophylaxis in children with ALL	Ongoing	<b>Not a COI.</b> BMS does not market any products for the diagnosis or treatment of bleeding disorders.
Pfizer	Steering Committee Personal income Topic – VTE treatment in pediatrics	Ongoing	<b>Indirect COI.</b> Pfizer markets recombinant factor VIII and factor IX for the treatment of Hemophilia A and B. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. Pfizer also markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD. Pfizer markets contraceptive estrogen products that could be used in the management of VWD symptoms in women. <b>Dr. O'Brien reported that this became an unpaid position as of March 2018 and she agrees to forgo all transfers of value for this activity during the guideline development process.</b>
CSL Behring	Program Chair for 2-day advisory board on diagnosis and management of VWD	June 24, 2017	<b>Not a COI.</b> CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. O'Brien has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Shire	VOICE Advisory Board Consultant – 2 hour virtual advisory board Topic – raising awareness of VWD	September 7, 2017	<b>Not a COI.</b> Shire markets recombinant von Willebrand factor for the treatment of VWD and anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. O'Brien has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Shire	Hemophilia / VWD 2-day Advisory Board	September 2016	<b>Not a COI.</b> As noted above, Shire markets products that could be addressed by the guidelines. However, this activity concluded prior to initiation of the guidelines, and Dr. O'Brien has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Shire	VWD 1-Day Advisory Board	November 2016	<b>Not a COI.</b> As noted above, Shire markets products that could be addressed by the guidelines. However, this activity concluded prior to initiation of the guidelines, and Dr. O'Brien has agreed to avoid direct financial conflicts for the duration of the guideline development process.
GSK	DSMB Member for study of VTE treatment	June 2016	<b>Not a COI.</b> GSK does not market any products for the diagnosis or treatment of bleeding disorders. However, this activity concluded prior to initiation of the guidelines.

### My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.



<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bristol Myers Squibb	Apixaban prophylaxis in newly diagnosed ALL patients Funding to institution	National PI	Ongoing	<b>Not a COI.</b> As noted above, BMS does not market any products for the diagnosis or treatment of bleeding disorders.

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

See list of review articles and lectures below. Primarily these talk about the importance of a detailed bleeding history, how formal bleeding assessment tools can help guide the diagnostic evaluation, and what treatment options are available for women with bleeding disorders. None of the presentations/chapters recommend one type of treatment over another

1. Ragni MV, O'Brien SH. Consultative Hematology II: Women's Health Issues. American Society of Hematology Self-Assessment Program, 5th edition, 2013.
2. O'Brien SH. Bleeding scores: are they really useful? Hematology Am Soc Hematol Educ Program 2012; 2012:152-6. PMID: 23233574

3. O'Brien SH. Common management issues in pediatric patients with mild bleeding disorders. *Sem Thromb Hemost* 2012 Oct; 38(7): 720-6. PMID: 23034827
4. Diagnosing Von Willebrand Disease: The Value of the Bleeding Assessment Tool. National Hemophilia Foundation's 69<sup>th</sup> Annual Meeting. August 25, 2017, Chicago, IL
5. Making Strides Towards Improving Care for Women and Girls With Bleeding Disorders. Hemophilia Federation of America and Foundation for Women and Girls with Blood Disorders (HFA and FWGBD) Webinar. August 17, 2017
6. When Women Bleed: Issues in Young Women's Hematology. Hematology Grand Rounds. Cincinnati Children's Hospital Medical Center. August 24, 2016, Cincinnati, OH
7. When Women Bleed: Issues in Young Women's Hematology. Pediatric Hematology/Oncology Grand Rounds Children's Medical Center of Dallas. February 23, 2016, Dallas, TX
8. Managing Heavy Menses and Pregnancy in Patients with Inherited Bleeding Disorders International Society of Thrombosis and Haemostasis (ISTH) Academy Webinar. September 24, 2014
9. Young Women's Hematology: Diagnostic and Management Issues. Hemophilia of Georgia Annual State Meeting. March 7, 2014, Atlanta, GA
10. Bleeding Scores: Are They Really Useful?. Education Session. American Society of Hematology Annual Meeting, December 8, 2012, Atlanta, GA

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
National Heart, Lung, and Blood Institute	R21 – Quality of care in Women with VWD Use of large insurance database to look at how often expert	PI	September 2018

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
	recommendations are followed in the diagnosis and management of women with heavy menses (was VW tested?), prior to hysterectomy for bleeding (was VW tested?), and testing VW levels during pregnancy in women with VWD		

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I have no concerns that I would not continue to receive the strong level of support I currently receive from my mentors and institution.

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
Foundation for Women and Girls with Blood Disorders	Undiagnosed, untreated blood disorders in women and young girls have medical consequences and unique issues at every life stage, creating the need for a foundation dedicated to education and awareness. We work to achieve this goal through raising awareness and educating the key healthcare providers for each particular life stage, and translating and disseminating provider information and research.	Medical Advisory Committee

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Pediatric Hemostasis and Thrombosis

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

My clinical practice involves caring for children with suspected or confirmed bleeding and clotting disorders.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:



## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Janssen	Advisory Board Meeting November 2019. Travel was paid by Janssen, but Dr. O'Brien did not accept any fees associated with this activity.	11/24/2019	<b>Not a COI.</b> Janssen does not make any products for the diagnosis and management of VWD.
Bristol Myers Squibb	Update 11/25/2019  Steering Committee Principal Investigator Travel Reimbursement Topic – VTE prophylaxis in children with ALL Ongoing	11/22/2017	See part A BMS is a pharmaceutical company that does not market any products for the diagnosis or treatment of bleeding disorders. However, BMS does market an anticoagulation therapy that may be addressed by PICO question 3. However, these products are marketed to a large population and VWD is a rare disease. Any effects on the company are expected to be negligible and do not present a conflict of interest.

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	Management of VWD
----------------------------	-------------------

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/2017; Castano, Kunkle 03/16/2018; Cheung, 5/07/2018	No	Yes	<p>Dr. O'Brien has one indirect COI with Pfizer, she holds a position in their Steering Committee (unpaid as of March 2018) and advises on VTE treatment in pediatrics. She agreed to forgo any payments or other transfers of value for this activity through the guideline development process. Pfizer markets products for the treatment of VWD that may be affected by the scope of the guidelines.</p> <p>Dr. O'Brien reports several recent paid activities with Shire and CSL Behring, companies that can be affected by the guidelines. She has agreed to avoid direct financial conflicts with these companies for the duration of the guideline development process.</p>
Castano, 11/25/2019	No	Yes	<p>Dr. O'Brien has one indirect COI with Pfizer, see above.</p> <p>Dr. O'Brien also has a relationship with Bristol Myers Squibb, who market triangulation therapies that can be affected by PICO question 3. However, these products are marketed to a large population and VWD is a rare disease. Any effects on the company are expected to be negligible and do not present a conflict of interest.</p>
Castano, 7/22/2020	No	Yes	On July 3, 2020 Dr. O'Brien confirmed all information on this form.

### Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

### Other Notes

Dr. O'Brien specializes in Pediatric Hemostasis and Thrombosis. In her clinical practice she cares for children with suspected or confirmed bleeding and clotting disorders. She has published review articles about VWD assessment, including the importance of a detailed bleeding history, how formal bleeding assessment tools can help guide the diagnostic evaluation, and what treatment options are available for women with bleeding disorders.

Dr. O'Brien is a PI for an NHLBI-funded study about adherence to recommended care in women with VWD. She also serves on the Medical Advisory Committee of the Foundation for Women and Girls with Blood Disorders.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novo Nordisk	Honoraria for speaker's bureau, consultancy (advisory board committee) and grant review. Travel support.	23-Nov-2017	<b>Not a COI.</b> Novo Nordisk markets recombinant factor VIIa and a recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Shire	Honoraria for speaker's bureau, consultancy (advisory board committee).	10-Nov-2017	<b>Not a COI.</b> Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Pfizer	Honoraria for speaker's bureau, consultancy (advisory board committee)	30-Sep-2017	<b>Not a COI.</b> Pfizer markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD. Pfizer also markets oral contraceptive estrogen products that could be used in the management of VWD symptoms in women. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Grifols	Honoraria for grant review	30-Sep-2017	<b>Not a COI.</b> Grifols markets an antihemophilic factor/von Willebrand factor complex indicated for the treatment of VWD in patients for whom desmopressin is either ineffective or contraindicated. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Biomarin	Consultancy (advisory board committee)	4-Oct-2017	<b>Not a COI.</b> BioMarin markets products for rare genetic diseases that do not include bleeding disorders. They have one pipeline product in Phase 2 for treatment of hemophilia A. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
			direct financial conflicts for the duration of the guideline development process.
CSL Behring	Consultancy (advisory board committee)	7-Jul-2017	<b>Not a COI.</b> CSL Behring markets human plasma-derived von Willebrand factor and FVIII concentrate and nasal desmopressin for the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid direct financial conflicts for the duration of the guideline development process.
Roche	Honoraria for speaker's bureau and consultancy (advisory board committee). Travel support and meeting registration.	12-Dec-2017	<b>Not a COI.</b> Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand factor. Outside the US, Roche markets products for the prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors. This activity concluded prior to initiation of the guidelines, and Dr. Ozelo has agreed to avoid direct financial conflicts for the duration of the guideline development process.

### My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novo Nordisk	Phase 3 clinical trial for hemophilia A new drug (N8-GP)	PI	ongoing	<b>Indirect COI.</b> As noted above, Novo Nordisk markets products that could be affected by the guidelines.
Biogen-Bioveractiv	Phase 4 clinical trial for hemophilia A new drug (Eloctate PUP study)	PI	ongoing	<b>Indirect COI.</b> Bioverativ markets recombinant factor VIII for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWD in the treatment of VWD.
Shire	Phase 4 clinical trial for hemophilia A (AHEAD study)	PI	ongoing	<b>Indirect COI.</b> As noted above, Shire markets products that could be affected by the guidelines.



<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire	Investigator Initiated Research (IIR) involving hemophilia A patients	PI	ongoing	<b>Indirect COI.</b> As noted above, Shire markets products that could be affected by the guidelines.
Pfizer	Investigator Initiated Research (IIR) involving musculoskeletal complications among patients with hemophilia	PI	ongoing	<b>Indirect COI.</b> As noted above, Pfizer markets products that could be affected by the guidelines.

### Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Novo Nordisk Haemophilia Foundation	Member of council	unpaid	ongoing	<b>Indirect COI.</b> Although this activity is unpaid and not related to VWD, as noted above, Novo Nordisk markets products that could be affected by the guidelines.

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I presented the diagnosis and impact of aging in the von Willebrand factor during the Annual Brazilian Hematology Congress (HEMO 2016). I am also co-author of three publications involving the topic of von Willebrand disease:

Kaur H, Ozelo M, Scovil S, James PD, Othman M. Systematic analysis of bleeding phenotype in PT-VWD compared to type 2B VWD using an electronic bleeding questionnaire. Clin Appl Thromb Hemost. 2014 Nov;20(8):765-71. doi: 10.1177/1076029614543825. Toukh M, Ozelo MC, Angelillo-

Scherrer A, Othman M. A novel use of thromboelastography in type 2B von Willebrand disease. *Int J Lab Hematol*. 2013 Dec;35(6):e11-4. doi: 10.1111/ijlh.12095.

Hamilton A, Ozelo M, Leggo J, et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. *Thromb Haemost*. 2011 Mar;105(3):501-8. doi: 10.1160/TH10-08-0523.

## Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)	Red blood cell diseases: Pathophysiology and new therapeutic approaches	One of the PIs in the project coordinated by Prof. Fernando Costa	ongoing
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)	Evaluation of molecular changes and immunological implications of primary immunodeficiency syndrome, Wiskott-Aldrich syndrome	PI	ongoing

## Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

Don't know

No

Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I already hold a leading position and expert role in the field related to bleeding disorders management in my institution and in Latin America. I believe as part of the panel of experts for the development of this guideline, this will reinforce this position, but will not directly change the confidence that I achieved during the years among my peers.

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>
Brazilian Ministry of Health	Technical expert committee	When request, I may act as volunteer member of a technical expert committee to evaluate the Brazilian program for bleeding disorders, organized by the Ministry of Health
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)	Member of hemostasis committee	Help the Brazilian society of Hematology and Transfusion Medicine in the development of meetings, educational support and any other relevant topic regarding hemostasis

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

I am hematologist with expertise in hemostasis, and for the last seven years, my career is strongly focused on the management of bleeding disorders.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I routinely evaluate patients with bleeding disorders, and von Willebrand disease is one of the possible diagnosis. I investigate this diagnosis and recommend the treatment, including the

prescription when it is necessary, for several different situations. In Brazil, all the medications and products are provided by the Brazilian Ministry of Health, and I am not involved in the purchase of these products.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Novo Nordisk	HERO Symposium during the NHF Hemophilia Congress in Glasgow, May 20, 2018	6/8/2018	<b>Indirect COI.</b> Novo Nordisk markets recombinant factor VIII that may be used in conjunction with recombinant VWF in the treatment of VWD.
BioMarin	Speaker at Hemophilia Gene Therapy Symposium during the ISTH meeting in Dublin, July 20, 2018	6/8/2018	<b>Not a COI.</b> As noted above, BioMarin does not market any products for the diagnosis or treatment of VWD.
N/A	Speaker during ASH Today program in conjunction with the Brazilian Association of Hematology and Transfusion Medicine (ABHH) – date TBD	6/8/2018	<b>Not a COI.</b>
Pfizer	PI - Phase 2/3 clinical trial for hemophilia A new drug anti-TFPI (PF-06741086)	1/13/2020	<b>Indirect COI.</b> As noted above, Pfizer markets products for the treatment of VWD.
Pfizer	PI - Phase 3 Gene therapy clinical trial for hemophilia B (BeneGene-2)	1/13/2020	<b>Indirect COI.</b> See above.
Bioverativ/Sanofi	PI- Phase 3 clinical trial for hemophilia A new rFVIII-Fc-VWF-XTEN (BIVV001)	1/13/2020	<b>Indirect COI.</b> As noted above, Bioverativ markets products for the treatment of VWD.
BioMarin	PI- Phase 3 Gene therapy clinical trial for	1/13/2020	<b>Not a COI.</b> See above.



<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	hemophilia A (BMN 270-301)		

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/11/2017; Castano, 3/15/18; Kunkle, 3/16/18; Cheung, 5/07/2018	No	Yes	<p>Dr. Ozelo has potential indirect COIs with companies that may be affected by the guidelines depending on scope including Novo Nordisk (PI for research about a new drug for hemophilia A and unpaid role as council member of the Novo Nordisk Hemophilia Foundation), Biogen-Bioveractiv (PI for research about a new drug for hemophilia A), Shire (PI for research about a new drug for hemophilia and PI for research about hemophilia A), and Pfizer (PI for research about musculoskeletal complications among patients with hemophilia).</p> <p>Dr. Ozelo reports recent paid activities with several companies that may be affected by the guidelines (Novo Nordisk, Shire, Pfizer, Grifols, CSL Behring, and Roche), but she has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.</p>
Castano, 7/30/2018	No	See above	Dr. Ozelo has an indirect conflict with Novo Nordisk. She was a paid speaker during the World Hemophilia Congress 2018. See part D for details.
Castano, 11/25/2019	No	Yes	Dr. Ozelo has several indirect financial conflicts with Shire (PI for research about a new drug for hemophilia and PI for research about hemophilia A); with Pfizer and Pfizer (PI for research about musculoskeletal complications among patients with hemophilia); Novo Nordisk (PI for research about a new drug for hemophilia A and unpaid role as council member of the Novo Nordisk Hemophilia Foundation); and Biogen-Bioveractiv

			(PI for research about a new drug for hemophilia A).
1/15/2020	No	Yes	Disclosure: Dr. Ozelo disclose two research activities with Pfizer and one with Bioverativ/Sanofi that are indirect conflicts of interest because this companies market products for the treatments of VWD, see part D.
Castano, 7/22/2020	No	Yes	On July 7, 2020 Dr. Ozelo confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Ozelo is a hematologist. In her clinical practice she evaluates and treats patients with bleeding disorders including VWD. She has presented on and authored scientific reports about VWD. In addition to the industry-funded research described above, she is the principal investigator on research funded by nonprofit foundations and councils about hematologic diseases. As a member of a technical expert committee of the Brazilian Ministry of Health, Dr. Ozelo helps evaluate a health program for patients with bleeding disorders. Dr. Ozelo is also a member of the Hemostasis Committee of the Brazilian Society for Hematology.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

Company	Description	End Date	For ASH Internal Use
Bayer	Meeting registration and travel support	July 2017	<b>Not a COI.</b> Bayer markets products that could be used in the management of VWD symptoms in women. This paid activity concluded prior to appointment to the guidelines panel. Dr. Tosetto has agreed to avoid direct financial conflicts with the affected companies during the guideline development process.
Pfizer	Meeting registration and travel support	December 2016	<b>Not a COI.</b> Pfizer markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD. Pfizer markets estrogen products that could be used in the management of VWD symptoms in women. This paid activity concluded prior to appointment to the guideline panel. Dr. Tosetto has agreed to avoid direct financial conflicts with the affected companies during the guideline development process.
Werfen	Speakers’ bureau	October 2017	<b>Not a COI.</b> Werfen specializes in non-invasive test performed on biological samples. Werfen markets a line of assays used in the diagnosis of VWD, including VWF:Ag, VWF:CB, VWF:RCo, and VWF:Controls. Currently Werfen does not market any products for the treatment of VWD.
Stago	Speakers’ bureau	October 2016	<b>Not a COI.</b> Stago markets assays used in the diagnosis of VWD, including VWF:Ag, VWF:CH, VWF:VIII, VWF:RCo. They do not market products for the treatment of VWD. This paid activity concluded prior to appointment to the guideline panel. Dr. Tosetto has agreed to avoid direct financial conflicts with affected companies during the guideline development process.

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,



markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood 2015;125:907-914.

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

### Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

N/A

### Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Diagnosis and treatment of VWD patients referred to the Hemophilia & Thrombosis Center, San Bortolo Hospital, Vicenza, Italy

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Novo Nordisk	Travel grant (San Diego 2018 ASH Meeting)	9/9/2019	<b>Indirect COI.</b> Novo Nordisk markets recombinant factor VIII that may be used in conjunction with recombinant VWF in the treatment of VWD.
Bayer	Advisory Board Meeting on PEGylated EHL FVIII (Jivi) for treatment of Hemophilia A patients (June 2019)	9/9/2019	<b>Not a COI.</b> Although Bayer markets hormonal products that can be affected by the guidelines, since these products are marketed to a large population, and VWD is a rare disease, any effects on the company are expected to be negligible and do not present a conflict of interest.
Werfen	Speaker activity, October 2019	7/7/2020	<b>Indirect COI.</b> Werfen is a diagnostic company that specializes in non-invasive test performed on biological samples. They market a line of assays used in the diagnosis of VWD, used for the analysis of blood samples. They do not have any marketed or pipeline products indicated for the treatment of VWD.

# Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Management of VWD
----------------------------	--

## Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/12/2017; Castano, Kunkle, 3/13/18; Cheung, 5/07/2018	No	No	Dr. Tosetto has agreed to avoid any direct financial conflicts of interest with companies that could be affected by the guidelines for the duration of the guideline development process.
Castano, 11/20/2019	No	Yes	New Disclosures: on September 9, 2019 Dr. Tosetto disclosed a new activity with Novo Nordisk which is an indirect conflict, see part D.
Castano, 7/22/2020	No	Yes	On July 7, 2020 Dr. Tosetto disclosed a new activity with Werfen which constitutes an indirect financial conflict. Also, on July 7, 2020 Dr. Tosetto confirmed all information on this form.

## Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

## Other Notes

Dr. Tosetto is a hematologist. In his clinical practice, he diagnoses and treats patients with VWD. He published a 2015 How I Treat article in *Blood* about patients with Type 2 VWD.



# ASH Guideline Panel Declaration of Interests Form

## Part A. Direct Financial Interests in or Relationships With Companies

### Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each employment relationship.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

### Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.



<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

### Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Shire	Medical Advisory Board	October 14, 2017	<b>Not a COI.</b> Shire markets recombinant von Willebrand Factor for the treatment of VWD and an anti-inhibitor coagulant complex used to control bleeding in patients with severe disease who do not respond to other treatments. They also market recombinant factor VIII products for the treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD. This activity concluded prior to initiation of the guidelines, and Dr. Weyand has agreed to avoid direct financial conflicts for the duration of the guideline development process.

### My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

# Part B. Indirect Financial Interests in or Relationships With Companies

## Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
NHF/Shire Clinical Fellowship	Genetics of coagulation in zebrafish	PI	12/31/2017	<b>Not a COI.</b> Although Shire may be affected by the guidelines (see above), this research activity concluded prior to initiation of the guidelines.
HTRS/Novo Nordisk Mentored Research Award	Genetics of coagulation in zebrafish	PI	06/30/2019	<b>Indirect COI.</b> Novo Nordisk markets recombinant factor VII for bleeding in patients with severe disease who are not responsive to other treatments and a recombinant factor VIII for treatment of Hemophilia A. Recombinant factor VIII may be used in conjunction with

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
				recombinant VWF in the treatment of VWD.
ATHN (The American Thrombosis and Hemostasis Network)	ATHN9: A Real World Safety and Efficacy Study of Factor Replacement for Clinically Severe Von Willebrand Disease	National co-PI	Ongoing	<b>Indirect COI.</b> ATHN is a non-profit organization dedicated to improving the lives of people affected by bleeding and clotting disorders. This study, currently funded by Shire, looks at the natural history of VWD and the use of factor replacement. There is no dedicated treatment arm as the study is observations, however Shire markets products that may be affected by the guidelines.
Roche/ Genentech	Emicizumab clinical trial	Site co-investigator	ongoing	<b>Indirect COI.</b> Roche markets an assay (RISTOtest) for the in vitro determination of von Willebrand Factor. Outside the US, Roche also markets a prophylactic treatment of bleeding episodes in patients with hemophilia A with factor VIII inhibitors.
ApoPharma	Ferriprox clinical trial	Site PI	ongoing	<b>Not a COI.</b> ApoPharma does not market any products for the diagnosis or treatment of bleeding disorders, including VWD.
BMS/Pfizer	COG trial for apixaban in ALL	Site co-investigator	ongoing	<b>Indirect COI.</b> Pfizer markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD. Pfizer markets estrogen products that could be used in the management of VWD symptoms in women.
Shire	PUPS Hem A clinical trial	Site PI	ongoing	<b>Indirect COI.</b> As noted above, Shire markets products that could be addressed by the guidelines.

## Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

<i>Organization</i>	<i>Description and role</i>	<i>Paid or Unpaid?</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

## Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes

If yes, please explain:

## Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

### Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

### Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

1. I co-authored a chapter in the Bethesda Handbook of Clinical Hematology (currently in press) which included a section on VWD treatment. In this section, we discussed the use of DDAVP, VWF concentrates, antifibrinolytics, and avoidance of antiplatelet medications.
2. I am currently co-authoring a letter to the editor about the use of recombinant vWF in a patient with acquired vWD. We discuss that this treatment was appropriate for this patient due to a severely elevated factor 8 level in the patient which precluded us from using factor 8 containing products.

### Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

### Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

## Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My mentor and institution are incredibly supportive of me and my career. They would be in full support of my involvement and contributions, regardless of any reactions from elsewhere.

## Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.



<i>Organization</i>	<i>Relevant Policy Position</i>	<i>Your Role</i>

## Clinical Practice

9. Do you see patients clinically?

No

Yes

If yes, what is your primary specialty or subspecialty?

Pediatric hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I diagnose and treat many patients with von Willebrand disease in my clinical practice.

## Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

No

Yes

If yes, please describe:

## Part D. New Declarations (ASH Internal Use)

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Biogen	<5,000 in stock (owned by husband)	6/5/2018	<b>Indirect COI.</b> Biogen markets recombinant factor VIII that may be used in conjunction with recombinant VWD in the treatment of VWD.
Portola	<\$10,000 in stock (owned by husband)	6/5/2018	<b>Not a COI.</b> The company does not market products for the treatment or diagnosis of VWD.
Kedrion Biopharma	Advisory Board	7/23/2018	<b>Not a COI.</b> The company does not market products for the diagnosis or treatment of VWD.
Bayer	Advisory Board	4/5/2019	<b>Not a COI.</b> Bayer is a pharmaceutical company that markets hormonal products that can be used to treat women with VWD. However, they market to a large population and VWD is a rare disease. Any effects on the company are expected to be negligible and do not present a conflict of interest.
Novo Nordisk	Site Investigator study on Hemophilia.	1/24/2020	<b>Indirect COI.</b> Novo Nordisk markets recombinant factor VIII. Recombinant factor VIII may be used

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			in conjunction with recombinant VWF in the treatment of VWD.
Bioverativ	Site Investigator study on Hemophilia.	1/24/2020	<b>Indirect COI.</b> Bioverativ markets recombinant factor VIII. Recombinant factor VIII may be used in conjunction with recombinant VWF in the treatment of VWD.
Pfizer	Site Investigator study on anticoagulation medication.	1/24/2020	<b>Indirect COI.</b> Pfizer markets a tranexamic acid. Tranexamic acid is used in the treatment of bleeding episodes in patients with VWD.
Biomarin	Co-investigator, gene therapy in hemophilia.	1/24/2020	<b>Not a COI.</b> Biomarin is not an affected company.
Biomarin	Travel, March 2019	1/24/2020	<b>Not a COI.</b> See above.
N/A	Co-author manuscript on the use of emicizumab in type 3 VWD with inhibitors.	1/24/2020	<b>Not a COI.</b> The research for this manuscript was not funded by industry.
Aptevo Therapeutics	Advisory Board	7/2/2020	<b>Not a COI.</b> Aptevo is not an affected company.
N/A	Co-authored article on misdiagnosis of vWD (Jaffray J, Staber JM, Malvar J, et al. Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: A multi-center study [published online ahead of print, 2020 May 17]. Am J Hematol. 2020;10.1002/ajh.2586	7/2/2020	<b>Not a COI.</b>

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	9. doi:10.1002/ajh.25869)		

## Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH ISTH NHF WFH Guidelines on the Management of von Willebrand Disease
----------------------------	---

### Summary of ASH Judgments About Financial Conflicts

<i>Reviewer name and date</i>	<i>Direct Financial Conflicts?</i>	<i>Indirect Financial Conflicts?</i>	<i>Management Notes</i>
Senerth, 12/12/2017; Castano, Kunkle, 3/14/18; Holter-Chakrabarty, 5/07/2018	No	Yes	<p>Dr. Weyand has indirect COIs with companies that may be affected by the guidelines depending on scope, including Novo Nordisk (PI on research about genetics of coagulation in zebrafish), Roche/Genentech (co-investigator on research about emicizumab), BMS/Pfizer (site co-investigator on research about apixaban in ALL), Shire (site PI on research about Hemophilia Type A and ATHN national co-PI on VWD observational study).</p> <p>Dr. Weyand reports a recent paid activity with Shire, a company that can be affected by the guidelines, but she has agreed to avoid direct financial conflicts with affected companies for the duration of the guideline development process.</p>
Castano, 6/17/2018	No	Yes	Dr. Weyand disclosed that her husband owns stock in Biogen and Portola. Biogen makes factor VIII, which may be used to treat VWD, see part D. Portola does not market any products for VWD.
Castano, 7/27/2018	No	Yes	Dr. Weyand disclosed that she will participate on an advisory board for Kedrion Biopharma, a company that does not market products for VWE.
Castano, 4/5/2019	No	Yes	Dr. Weyand disclosed that she will participate on an advisory board or Bayer. See above.
Castano, 9/22/2019	No	Yes	Dr. Weyand had no new disclosures after a COI check-in phone call with ASH staff.
Castano, 1/24/2020	No	Yes	On January 24, 2020 Dr. Weyand disclosed several research related activities with Novo

			Nordisk, Bioverativ, and Pfizer, which are indirect financial conflicts. She also a research activity with Biomarin, which is not a conflict. Please see part D for details.
Castano, 7,22/2020	No	Yes	On July 2, 2020 Dr. Weyand disclosed an Advisory Board activity with Aptevo, which is not an affected company, she also disclosed the publication of a new article on VWD, see part D. On July 2, 2020 Dr. Weyand also confirmed all information on this form.

Summary of Direct Financial Conflicts

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Other Notes

Dr. Weyand is a hematologist. She specializes in pediatrics. In her clinical practice she diagnoses and treats patients with VWD.

Dr. Weyand co-authored a chapter in the Bethesda Handbook of Clinical Hematology, which includes a section about the use of DDAVP, VWF concentrates, antifibrinolytics, and avoidance of antiplatelet medications in the treatment of VWD. She is also co-authoring a letter to the editor about the use of recombinant vWF in a patient with acquired VWD.